Company news
Swedish Orphan Biovitrum Ab (OMXSTO:SOBI) news
Every Swedish Orphan Biovitrum Ab press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 2
Invitation: Sobi's NASP and Uncontrolled Gout call and webcast
September 10, 2025
FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout
September 10, 2025
Sobi has completed issues of class C shares
August 21, 2025
TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)
July 25, 2025
Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum
July 16, 2025
The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes
July 15, 2025
Invitation: Sobi's Q2 report
July 2, 2025
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)
July 1, 2025
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease
June 27, 2025
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
June 20, 2025
Sobi share new clinical data across multiple hematologic diseases at EHA 2025
June 12, 2025
Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
June 6, 2025
Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025
June 4, 2025
Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology
June 3, 2025
Sobi to share new clinical data and research at EULAR 2025
May 28, 2025
Sobi publishes Q1 2025 report: Portfolio continues to deliver
April 29, 2025
Sobi presents clinical data at WFH 2025 Comprehensive Care Summit
April 23, 2025